Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, +23

New England Journal of Medicine

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Manuel Cobo, +24

The Lancet Oncology

Non-small-cell Lung CancerMedicinePharmacologyImmune Checkpoint InhibitorPharmacotherapy +4

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

Scott Antonia, Hossein Borghaei, Suresh S. Ramalingam, +17

The Lancet Oncology

OncologyFour-year SurvivalImmune Checkpoint InhibitorCancer TreatmentPooled Analysis +3

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

George D. Demetri, Patricia Lo Russo, Iain R. Macpherson, +7

Clinical Cancer Research

OncologyCancer TherapeuticsMedicineMetronomic TherapyClinical Trials +12

Nivolumab Exposure–Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non–Small Cell Lung Cancer

Feng Yan, Xiaoning Wang, Gaurav Bajaj, +6

Clinical Cancer Research

CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC.

Matthew D. Hellmann, Scott Gettinger, Jonathan W. Goldman, +13

Journal of Clinical Oncology

ImmunologyPharmacotherapyImmunotherapeuticsMetronomic ChemotherapyCheckmate 012 +14

Simultaneous determination of sulforaphane and its major metabolites from biological matrices with liquid chromatography–tandem mass spectroscopy

Shruti Agrawal, Bożena Winnik, Brian Buckley, +3

Journal of Chromatography B

Chemical MeasurementBiochemistryMedicineNatural SciencesBioanalysis +12

A validated LC–MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: Application to a clinical pharmacokinetic study

Michael Furlong, Shruti Agrawal, Dara Hawthorne, +4

Journal of Pharmaceutical and Biomedical Analysis

Hematological MalignancyTherapeutic Drug MonitoringOncologyHealth SciencesAnti-leukemic Agent Dasatinib +10

PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors.

Scott S. Tykodi, Julie R. Brahmer, Wen‐Jen Hwu, +14

Journal of Clinical Oncology

Lymphoid NeoplasiaTumor ImmunologyCancer ImmunosurveillanceAnti-pd-l1 AntibodyMedicine +13

Abstract CT101: A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types

Xiaochen Zhao, Vijay Ivaturi, Mathangi Gopalakrishnan, +10

Cancer Research

Nivo ExposuresPharmacotherapyModel-based Exposure-responseDrug MonitoringRadiation Therapy Planning +14